Stock listing
BX Swiss:FLB Standard BioTools Inc. Aktie
Swiss listing (BX Swiss) of Standard BioTools Inc. · home listing NASDAQ:LAB
Follow Standard BioTools Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:LAB
$0.631 USD +0.061 (+10.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:LAB
- Day range
- $0.573 – $0.650 USDNov 20, 2026
- Volume
- 2.81M sharesNov 20, 2026
- Market cap
- $249.1M USDAt the close on Nov 20, 2026 · price × 394.7M shares outstanding
- 52-week range
- $0.394 – $1.720 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $811,230 USDMedian day 1.04M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LAB · Home | $0.631 USD | +0.061 (+10.7%) | 2,808,206 | $0.629 | $0.650 | $0.573 | $0.570 | Close on Nov 20, 2026 |
| Frankfurt:FLB | €0.555 EUR | +0.040 (+7.8%) | — | €0.555 | €0.555 | €0.555 | €0.515 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LAB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.631 | +0.061 | +10.7% | $0.629 | $0.650 | $0.573 | 2,808,206 | |
| $0.570 | +0.031 | +5.7% | $0.550 | $0.592 | $0.527 | 697,449 | |
| $0.539 | -0.082 | -13.1% | $0.605 | $0.624 | $0.394 | 4,366,184 | |
| $0.621 | -0.086 | -12.2% | $0.701 | $0.710 | $0.603 | 639,075 | |
| $0.707 | +0.056 | +8.6% | $0.659 | $0.735 | $0.633 | 1,389,947 | |
| $0.651 | +0.008 | +1.3% | $0.652 | $0.680 | $0.643 | 365,495 | |
| $0.643 | -0.022 | -3.3% | $0.679 | $0.715 | $0.643 | 406,132 | |
| $0.665 | -0.029 | -4.2% | $0.687 | $0.689 | $0.655 | 327,234 | |
| $0.694 | +0.058 | +9.2% | $0.637 | $0.718 | $0.636 | 730,104 | |
| $0.636 | +0.014 | +2.2% | $0.630 | $0.644 | $0.610 | 1,122,557 | |
| $0.622 | +0.006 | +1.0% | $0.628 | $0.630 | $0.600 | 918,928 | |
| $0.616 | +0.005 | +0.9% | $0.605 | $0.630 | $0.605 | 1,015,170 | |
| $0.611 | +0.001 | +0.1% | $0.610 | $0.626 | $0.600 | 1,265,621 | |
| $0.610 | 0.000 | 0.0% | $0.611 | $0.628 | $0.600 | 1,708,226 | |
| $0.610 | -0.010 | -1.6% | $0.622 | $0.625 | $0.600 | 1,002,541 | |
| $0.620 | 0.000 | 0.0% | $0.620 | $0.630 | $0.610 | 445,300 | |
| $0.620 | 0.000 | 0.0% | $0.620 | $0.630 | $0.610 | 741,700 | |
| $0.620 | +0.020 | +3.3% | $0.600 | $0.630 | $0.590 | 1,037,000 | |
| $0.600 | -0.010 | -1.6% | $0.620 | $0.620 | $0.590 | 643,500 | |
| $0.610 | -0.030 | -4.7% | $0.630 | $0.650 | $0.590 | 853,000 | |
| $0.640 | -0.010 | -1.5% | $0.630 | $0.670 | $0.630 | 1,201,700 | |
| $0.650 | +0.010 | +1.6% | $0.630 | $0.670 | $0.630 | 399,600 | |
| $0.640 | 0.000 | 0.0% | $0.640 | $0.650 | $0.620 | 561,400 | |
| $0.640 | +0.010 | +1.6% | $0.620 | $0.650 | $0.620 | 414,700 | |
| $0.630 | -0.030 | -4.5% | $0.660 | $0.660 | $0.630 | 647,300 | |
| $0.660 | +0.030 | +4.8% | $0.630 | $0.670 | $0.630 | 485,700 | |
| $0.630 | -0.030 | -4.5% | $0.640 | $0.680 | $0.630 | 1,186,500 | |
| $0.660 | 0.000 | 0.0% | $0.660 | $0.670 | $0.650 | 368,900 | |
| $0.660 | -0.030 | -4.3% | $0.690 | $0.690 | $0.650 | 494,600 | |
| $0.690 | +0.020 | +3.0% | $0.680 | $0.700 | $0.660 | 649,200 | |
| $0.670 | -0.010 | -1.5% | $0.670 | $0.680 | $0.640 | 1,906,400 | |
| $0.680 | -0.040 | -5.6% | $0.710 | $0.740 | $0.680 | 1,390,300 | |
| $0.720 | -0.040 | -5.3% | $0.770 | $0.800 | $0.720 | 1,397,600 | |
| $0.760 | +0.020 | +2.7% | $0.740 | $0.800 | $0.740 | 1,178,400 | |
| $0.740 | +0.010 | +1.4% | $0.730 | $0.760 | $0.730 | 786,500 | |
| $0.730 | -0.010 | -1.4% | $0.740 | $0.750 | $0.720 | 1,083,100 | |
| $0.740 | +0.030 | +4.2% | $0.720 | $0.740 | $0.710 | 1,591,100 | |
| $0.710 | -0.020 | -2.7% | $0.730 | $0.730 | $0.710 | 173,400 | |
| $0.730 | -0.010 | -1.4% | $0.750 | $0.750 | $0.720 | 479,000 | |
| $0.740 | 0.000 | 0.0% | $0.740 | $0.750 | $0.710 | 471,800 | |
| $0.740 | 0.000 | 0.0% | $0.740 | $0.770 | $0.740 | 743,900 | |
| $0.740 | -0.010 | -1.3% | $0.750 | $0.770 | $0.730 | 653,400 | |
| $0.750 | +0.010 | +1.4% | $0.740 | $0.770 | $0.740 | 1,346,500 | |
| $0.740 | -0.030 | -3.9% | $0.760 | $0.760 | $0.730 | 459,600 | |
| $0.770 | +0.040 | +5.5% | $0.720 | $0.770 | $0.700 | 2,694,900 | |
| $0.730 | +0.020 | +2.8% | $0.720 | $0.750 | $0.720 | 664,900 | |
| $0.710 | +0.020 | +2.9% | $0.690 | $0.740 | $0.690 | 982,300 | |
| $0.690 | -0.010 | -1.4% | $0.680 | $0.700 | $0.680 | 841,700 | |
| $0.700 | +0.010 | +1.4% | $0.690 | $0.710 | $0.680 | 695,600 | |
| $0.690 | 0.000 | 0.0% | $0.700 | $0.700 | $0.680 | 1,745,600 | |
| $0.690 | -0.040 | -5.5% | $0.710 | $0.720 | $0.680 | 1,211,500 | |
| $0.730 | +0.040 | +5.8% | $0.690 | $0.730 | $0.690 | 1,946,500 | |
| $0.690 | 0.000 | 0.0% | $0.700 | $0.730 | $0.670 | 2,839,500 | |
| $0.690 | +0.020 | +3.0% | $0.680 | $0.690 | $0.660 | 1,763,100 | |
| $0.670 | 0.000 | 0.0% | $0.680 | $0.710 | $0.660 | 2,120,500 | |
| $0.670 | +0.020 | +3.1% | $0.660 | $0.690 | $0.660 | 3,077,000 | |
| $0.650 | -0.010 | -1.5% | $0.660 | $0.660 | $0.640 | 1,973,100 | |
| $0.660 | +0.020 | +3.1% | $0.650 | $0.670 | $0.640 | 1,759,700 | |
| $0.640 | -0.010 | -1.5% | $0.660 | $0.670 | $0.640 | 1,260,400 | |
| $0.650 | 0.000 | 0.0% | $0.660 | $0.670 | $0.640 | 1,486,900 | |
| $0.650 | 0.000 | 0.0% | $0.650 | $0.660 | $0.640 | 1,337,300 | |
| $0.650 | 0.000 | 0.0% | $0.650 | $0.666 | $0.636 | 1,306,640 | |
| $0.650 | -0.020 | -3.0% | $0.667 | $0.699 | $0.645 | 1,341,616 | |
| $0.670 | +0.020 | +3.1% | $0.630 | $0.690 | $0.630 | 3,569,600 | |
| $0.650 | -0.020 | -3.0% | $0.680 | $0.700 | $0.630 | 2,009,900 |
- Ticker
- BX Swiss:FLB
- Asset type
- Stock
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Nov 19, 2026
Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business
Latest deck · Jun 8, 2026
Merger or Acquisition (June 2026)
Merger or acquisition · 8 slides
Latest news
Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business
Nov 19, 2026
Closed $0.631 (+10.7%) on Nov 20, 2026
ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific
Nov 3, 2026
Closed $0.611 (+0.1%) on Nov 3, 2026
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
Oct 5, 2026
Closed $0.72 (-5.3%) on Oct 6, 2026
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Sep 30, 2026
Closed $0.73 (-1.4%) on Oct 1, 2026
Standard BioTools: Q2 Earnings Snapshot
Aug 5, 2026
Closed $0.80 (+2.6%) on Aug 6, 2026
Standard BioTools Reports Second Quarter 2026 Financial Results
Aug 5, 2026
Closed $0.80 (+2.6%) on Aug 6, 2026
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Jul 28, 2026
Closed $0.79 (+2.6%) on Jul 28, 2026
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Jul 22, 2026
Closed $0.82 (-6.8%) on Jul 22, 2026
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Jul 20, 2026
Closed $0.85 (-4.5%) on Jul 20, 2026
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Jun 8, 2026
Closed $0.80 (-30.4%) on Jun 8, 2026
Standard BioTools Inc. on 6ix
- News releases
- 16 in the last 12 months · 88 in all · newest Nov 19, 2026 · oldest 2020
- Calls
- 17 calls with a replay · 17 with a transcript · latest May 6, 2025
- Decks
- 23 decks · latest Jun 8, 2026
Where Standard BioTools Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LAB · Home listing | NASDAQ | United States | USD |
| BOATS:LAB | BOATS | United States | USD |
| gettex:FLB | gettex | Germany | EUR |
| LS Exchange:A0RADJ | LS Exchange | Germany | EUR |
| Lang & Schwarz:A0RADJ | Lang & Schwarz | Germany | EUR |
| Frankfurt:FLB | Frankfurt | Germany | EUR |
| BX Swiss:FLB · This page | BX Swiss | Switzerland | CHF |
| Dusseldorf:FLB | Dusseldorf | Germany | EUR |
| Munich:FLB | Munich | Germany | EUR |
| Stuttgart:FLB | Stuttgart | Germany | EUR |
| Tradegate:FLB | Tradegate | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$185.2M USD
- P/E
- 1.9×
- EV/sales
- −2.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- 52.2%
- Operating margin
- −97.5%
- Net margin
- 157.6%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.67
Forecasts
1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.35 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.10 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Michael Egholm | President and Chief Executive Officer |
| Alex Kim | CFO |
| Sean MacKey | COO |
| Standard BioTools’ | Investor Relations department |
| Anders Davas | Senior Vice President, Global Operations |
| Betsy Jensen | Chief Human Resources Officer |
| Mike Musgnug | CTO |
| Sean MacKay | Chief Business Officer |
Events
Calls
| Call | When | Status |
|---|---|---|
| Standard BioTools (NASDAQ:LAB) Q1 2025 Earnings Call | Tue, May 06, 2025 · 4:30 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 4:30 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 4:30 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q2 2024 Earnings Call | Wed, Jul 31, 2024 · 4:30 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q1 2024 Earnings Call | Wed, May 08, 2024 · 4:30 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q4 2023 Earnings Call | Wed, Feb 28, 2024 · 8:30 AM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 4:30 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q2 2023 Earnings Call | Tue, Aug 08, 2023 · 5:00 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q1 2023 Earnings Call | Tue, May 09, 2023 · 5:00 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q4 2022 Earnings Call | Tue, Feb 14, 2023 · 5:00 PM ET | Replay |
All 17 calls
| Call | When | Status |
|---|---|---|
| Standard BioTools (NASDAQ:LAB) Q3 2022 Earnings Call | Tue, Nov 08, 2022 · 5:00 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 4:30 PM ET | Replay |
| Standard BioTools (NASDAQ:LAB) Q1 2022 Earnings Call | Thu, May 05, 2022 · 5:00 PM ET | Replay |
| Fluidigm Corporation (FLDM) Q3 2021 Earnings Call | Mon, Nov 08, 2021 · 4:30 PM ET | Replay |
| Fluidigm Corporation (FLDM) Q2 2021 Earnings Call | Thu, Aug 05, 2021 · 5:00 PM ET | Replay |
| Fluidigm Corporation (FLDM) Q1 2021 Earnings Call | Thu, May 06, 2021 · 5:00 PM ET | Replay |
| Fluidigm Corporation (FLDM) Q4 2020 Earnings Call | Wed, Feb 10, 2021 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 17, 2026 | −8.2% |
| Q2 2026 | Aug 5, 2026 · After close | +2.6% |
| Q1 2026 | May 5, 2026 · After close | −1.0% |
| Q4 2025 | Feb 18, 2026 | +2.7% |
| Q3 2025 | Nov 4, 2025 · After close | −4.2% |
| Q2 2025 | Aug 11, 2025 · After close | +2.3% |
| Q1 2025 | May 6, 2025 · After close | −3.8% |
| Q4 2024 | Feb 26, 2025 · Before open | −7.1% |
| Q3 2024 | Oct 30, 2024 · After close | +4.3% |
| Q2 2024 | Jul 31, 2024 · After close | −36.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +7.6% |
| Q4 2023 | Feb 28, 2024 · After close | −5.1% |
| Q3 2023 | Nov 7, 2023 · After close | −4.5% |
| Q2 2023 | Aug 8, 2023 · After close | +7.6% |
| Q1 2023 | May 9, 2023 · After close | +12.5% |
| Q4 2022 | Feb 14, 2023 · After close | +1.4% |
| Q3 2022 | Nov 8, 2022 · After close | −5.1% |
| Q2 2022 | Aug 8, 2022 · After close | −17.6% |
| Q1 2022 | May 5, 2022 · After close | −2.0% |
| Q4 2021 | Feb 17, 2022 · After close | +7.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (June 2026) | Merger or acquisition | 8 slides | Jun 8, 2026 |
| Merger or Acquisition (June 2026) | Merger or acquisition | 32 slides | June 2026 |
| Q1 2025 Earnings Presentation | Earnings | 22 slides | May 6, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 24 slides | Feb 26, 2025 |
| Investor Presentation (January 2025) | Investor deck | 31 slides | Jan 13, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 21 slides | Oct 30, 2024 |
| Investor Presentation (September 2024) | Investor deck | 25 slides | Sep 5, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 21 slides | Jul 31, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 24 slides | May 8, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 34 slides | Feb 28, 2024 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2024) | Investor deck | 28 slides | Jan 8, 2024 |
| Q3 2023 Earnings Presentation | Earnings | 24 slides | Nov 7, 2023 |
| Merger or Acquisition (October 2023) | Merger or acquisition | 15 slides | Oct 4, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 26 slides | Aug 8, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 19 slides | May 9, 2023 |
| FY2022 Earnings Presentation | Earnings | 21 slides | Feb 14, 2023 |
| Investor Presentation (January 2023) | Investor deck | 23 slides | Jan 9, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 13 slides | Nov 8, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 25 slides | Aug 8, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 31 slides | May 5, 2022 |
| Fluidigm — Merger or Acquisition (February 2022) | Merger or acquisition | 21 slides | Feb 14, 2022 |
| Fluidigm — Investor Presentation (January 2017) | Investor deck | 24 slides | Jan 9, 2017 |
| Fluidigm — IPO Roadshow (January 2014) | IPO roadshow | 17 slides | Jan 29, 2014 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85.3M | 91.0M | 106.3M | 97.9M | 130.6M | 138.1M | 117.2M | 113.0M | 101.9M | 104.4M |
| Cost of revenue | 42.8M | 46.1M | 55.9M | 60.9M | 53.3M | 54.8M | 53.0M | 51.3M | 50.0M | 300.0K |
| Gross profit | 42.5M | 44.9M | 50.5M | 37.1M | 77.3M | 83.3M | 64.3M | 61.6M | 52.0M | 58.4M |
| Research and development | 26.0M | 28.8M | 25.9M | 37.4M | 37.9M | 36.5M | 31.6M | 30.0M | 30.8M | 38.4M |
| Selling, general and administrative | 109.9M | 103.1M | 87.5M | 102.3M | 98.9M | 97.9M | 84.5M | 79.8M | 79.5M | 93.2M |
| Operating income | -110.2M | -127.5M | -76.6M | -116.2M | -67.5M | -51.0M | -51.8M | -48.2M | -58.4M | -73.2M |
| Depreciation and amortization | 9.26M | 12.3M | 12.7M | 12.5M | 3.22M | 4.01M | 4.61M | 5.37M | 7.41M | 6.74M |
| EBITDA | -101.0M | -115.2M | -63.9M | -103.8M | -64.2M | -47.0M | -47.2M | -42.8M | -51.0M | -66.5M |
| Interest expense | 26.0K | 3.32M | 4.57M | 4.33M | 3.82M | 3.57M | 4.28M | 13.9M | 5.82M | 5.82M |
| Income before tax | -96.7M | -90.4M | -74.2M | -192.9M | -63.7M | -54.1M | -66.7M | -61.4M | -63.8M | -80.2M |
| Income tax | -37.9M | 542.0K | 452.0K | -2.83M | -4.42M | -1.08M | -1.92M | -2.41M | -3.26M | -4.19M |
| Net income | -74.9M | -138.9M | -74.7M | -190.1M | -59.2M | -53.0M | -64.8M | -59.0M | -60.5M | -76.0M |
| Earnings per share, basic | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 |
| Earnings per share, diluted | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 120.9M | 166.7M | 51.7M | 81.3M | 28.5M | 68.5M | 21.7M | 95.4M | 58.1M | 35.0M |
| Short-term investments | 66.7M | 126.1M | 63.2M | 84.5M | 0 | 0 | 37.0M | 0 | 5.08M | 24.4M |
| Receivables | 13.4M | 14.7M | 19.7M | 17.3M | 18.3M | 25.4M | 19.0M | 16.7M | 15.0M | 14.6M |
| Inventory | 20.0M | 20.7M | 20.5M | 21.5M | 20.8M | 19.7M | 13.9M | 13.0M | 15.1M | 20.1M |
| Current assets | 454.3M | 375.9M | 158.2M | 208.8M | 72.1M | 117.7M | 96.1M | 127.1M | 94.8M | 96.7M |
| Property, plant and equipment | 19.3M | 22.8M | 24.2M | 25.7M | 28.0M | 17.5M | 8.06M | 8.82M | 12.3M | 16.5M |
| Goodwill | 111.3M | 106.3M | 106.3M | 106.4M | 106.6M | 104.1M | 104.1M | 104.1M | 104.1M | |
| Total assets | 567.8M | 612.3M | 323.1M | 390.3M | 275.2M | 324.8M | 264.8M | 303.6M | 287.4M | 306.4M |
| Accounts payable | 5.41M | 5.05M | 9.24M | 7.91M | 10.6M | 9.22M | 5.15M | 4.03M | 4.21M | 3.97M |
| Current liabilities | 108.3M | 65.9M | 109.3M | 43.4M | 49.6M | 54.2M | 32.8M | 37.6M | 33.5M | 29.5M |
| Long-term debt | 299.0K | 299.0K | 3.98M | 62.8M | 64.2M | 54.2M | 53.8M | 172.1M | 195.2M | 195.0M |
| Total debt | 30.8M | 299.0K | 63.5M | 64.9M | 111.6M | 95.4M | 60.0M | 172.1M | 195.2M | 195.0M |
| Total liabilities | 143.5M | 140.6M | 159.9M | 160.5M | 180.6M | 185.7M | 111.2M | 231.5M | 256.4M | 253.2M |
| Shareholders' equity | 424.3M | 471.7M | -148.1M | -81.5M | 94.6M | 139.1M | 153.6M | 72.1M | 30.9M | 53.2M |
| Shares outstanding | 386.4M | 377.5M | 80.2M | 79.5M | 76.9M | 74.5M | 70.0M | 49.3M | 38.8M | 29.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -74.3M | -143.5M | -43.3M | -89.4M | -44.1M | -15.4M | -35.2M | -25.2M | -24.1M | -39.1M |
| Capital spending | -8.30M | -8.36M | -2.83M | -3.83M | -13.3M | -12.7M | -2.53M | -372.0K | -1.57M | -5.07M |
| Free cash flow | -82.6M | -151.8M | -46.1M | -93.2M | -57.3M | -28.1M | -37.7M | -25.6M | -25.7M | -44.2M |
| Cash from investing | 27.4M | 363.2M | 20.2M | -88.1M | -11.9M | 40.0M | -39.3M | 4.72M | 17.7M | 45.1M |
| Cash from financing | 570.0K | -102.6M | -6.81M | 230.8M | 16.0M | 20.9M | 2.79M | 57.7M | 29.0M | 116.0K |
| Dividends paid | -299.0K | -1.50M | ||||||||
| Share buybacks | 0 | -40.5M | -5.41M | -563.0K | 0 | -459.0K | -629.0K | 60.9M | 29.1M | -111.0K |
| Change in cash | -45.5M | 116.3M | -29.8M | 52.9M | -40.1M | 45.8M | -71.7M | 37.3M | 23.0M | 5.93M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 425 | Nov 19, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 19, 2026 | Management or board change | SEC |
| 425 | Nov 16, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 3, 2026 | Quarterly report | SEC |
| 425 | Nov 3, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 3, 2026 | Current report | SEC |
| 424B3 · Prospectus | Oct 30, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Oct 22, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 21, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Oct 21, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Oct 9, 2026 | Offer document | SEC |
| 425 | Oct 5, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 5, 2026 | Current report | SEC |
| 425 | Sep 30, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 30, 2026 | Material contract | SEC |
| S-4/A · Registration statement, amended | Sep 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 30, 2026 | Big-stake notice | SEC |
| 425 | Jul 29, 2026 | Other filings | SEC |
| 8-K/A · Current report, amended | Jul 29, 2026 | Current report | SEC |
| 425 | Jul 28, 2026 | Other filings | SEC |
| 425 | Jul 28, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 28, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| 425 | Jul 20, 2026 | Other filings | SEC |
| S-4 · Registration statement | Jul 20, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 9, 2026 | Big-stake notice | SEC |
| 425 | Jun 8, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 8, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 5, 2026 | Current report | SEC |
| 8-K · Current report | Jun 3, 2026 | Management or board change | SEC |
| SD · Specialized disclosure | May 29, 2026 | ESG report | SEC |
| 8-K · Current report | May 28, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 24, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| 8-K/A · Current report, amended | Feb 5, 2026 | Current report | SEC |
| 8-K · Current report | Jan 30, 2026 | Results | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 8-K · Current report | Sep 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 15, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 15, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 11, 2025 | Explanation request | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 1, 2025 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 20, 2025 | Management or board change | SEC |
| SD · Specialized disclosure | Jun 2, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 21, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 10, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 4, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 8-K · Current report | Jan 10, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 7, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 21, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 9, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Sep 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 30, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2024 | Management or board change | SEC |
| 8-K · Current report | Jul 31, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jun 28, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 26, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jun 25, 2024 | Other filings | SEC |
This page holds 200 of 1,005 filings. Open Filings
Cap table
Built by 6ix from Standard BioTools Inc.’s releases
- Common shares
- 394,711,296
- Fully diluted
- 394,711,296
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 394,711,296 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 394,711,296 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eli Casdin Other companies: GeneDx Holdings Corp. (Board Member · Since at least Apr 27, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past); EQRx Inc (Director · Sep 30, 2022 – Sep 30, 2022 · Past); Tenaya Therapeutics, Inc. (Director · Jun 10, 2022 – Nov 17, 2022 · Past); Century Therapeutics, Inc. (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Absci Corporation (Director · Jun 8, 2022 – Jun 8, 2022 · Past) | Director · Since at least Apr 4, 2022 |
| Carlos Paya Other companies: Collegium Pharmaceutical, Inc. (Director · Since at least May 15, 2025); Vaxcyte, Inc. (President, Immune Design Corp Chairman, Vaxcyte · Since at least Oct 27, 2021); Mallinckrodt Inc (Director · May 22, 2019 – Jun 16, 2022 · Past); Immune Design Corp (President and CEO, Director · Oct 30, 2015 – Apr 2, 2019 · Past) | Director · Mar 23, 2017 – Jun 14, 2023 · Past |
| Evan Jones Other companies: Veracyte, Inc. (Board Member · Since at least Oct 29, 2013); CapForce Inc. (Director · May 4, 2015 – May 17, 2021 · Past); Foundation Medicine Inc (Director · Sep 24, 2013 – Jul 31, 2018 · Past); CAS Medical Systems Inc (Director · Jun 20, 2012 – Jun 24, 2013 · Past) | Director · Dec 12, 2011 – Jul 31, 2017 · Past |
| Frank R. Witney Other companies: Alamar Biosciences, Inc. (Director · Since at least Apr 16, 2026); Cerus Corporation (Director · Since at least May 9, 2024); Revvity, Inc. (Director · Since at least May 1, 2024); Telesis Bio, Inc. (Director · Jul 6, 2023 – Jul 6, 2023 · Past) | Director · Since at least Jun 28, 2024 |
| Laura Clague Other companies: Travere Therapeutics, Inc. (Chief Financial Officer · Nov 17, 2014 – May 10, 2022 · Past); Turtle Beach Corporation (Director · Aug 23, 2010 – Aug 23, 2010 · Past); Genasys Inc. (Director · Dec 8, 2008 – Apr 27, 2022 · Past) | Director · Oct 30, 2018 – Jun 14, 2023 · Past |
| Nicolas M. Barthelemy Other companies: Repligen Corporation (Director · Since at least May 11, 2016); 908 Devices Inc. (Director · Dec 17, 2020 – Jun 15, 2022 · Past); Twist Bioscience Corporation (Director · Oct 24, 2019 – Nov 21, 2022 · Past) | Director · Mar 23, 2017 – Apr 1, 2022 · Past |
| Troy Cox Other companies: MapLight Therapeutics, Inc. (Chair of the Nominating and Corporate Governance Committee · Since at least Jun 23, 2026); Sophia Genetics SA (Board Member and Lead Independent Director · Since at least Jun 10, 2026) | Director · Since at least Jun 18, 2026 |
| Jeffrey G Black Other companies: Exagen Inc. (Chief Financial Officer · Since at least Sep 1, 2024) | SVP & Chief Financial Officer · May 15, 2024 – Aug 20, 2024 · Past |
| Thomas D Carey Other companies: EXACT Sciences Corporation (Director · Apr 29, 2013 – Jun 2, 2021 · Past) | Director · Since at least Jan 5, 2024 |
| Alex Kim | CFO · Since at least Nov 4, 2025 |
All 27 people
| Person | Seat |
|---|---|
| Ana K Stankovic | Director · Dec 15, 2020 – May 25, 2021 · Past |
| Anders Davas | Senior Vice President, Global Operations · Since at least Nov 5, 2026 |
| Betsy Jensen | Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Bill Colston | Director · Jun 15, 2022 – Jun 15, 2022 · Past |
| Colin McCracken | Chief Commercial Officer · Apr 30, 2019 – Feb 22, 2022 · Past |
| Gajus Vincent Worthington | CHIEF EXECUTIVE OFFICER, Director · May 20, 2016 – Aug 22, 2016 · Past |
| Hanjoon Alex Kim | Chief Financial Officer · Since at least Apr 4, 2022 |
| Jeremy Steven Davis | SVP Chief Commercial Officer · Apr 4, 2022 – Feb 21, 2023 · Past |
| Mai Chan Yow | See Remarks · Feb 17, 2012 – Feb 20, 2018 · Past |
| Michael Egholm | President and Chief Executive Officer · Since at least Apr 4, 2025 |
| Mike Musgnug | CTO · Since at least Nov 4, 2026 |
| Robert C Jones | See Remarks · May 20, 2016 – Aug 22, 2016 · Past |
| Sean MacKay | Chief Business Officer · Since at least May 21, 2025 |
| Sean MacKey | COO · Since at least Nov 4, 2026 |
| Standard BioTools’ | Investor Relations department · Since at least Nov 3, 2026 |
| Vikram Jog | Chief Financial Officer · Sep 20, 2017 – Feb 21, 2023 · Past |
| William Maxwell Smith | EVP, Legal Affairs · Oct 10, 2011 – Jun 20, 2016 · Past |
Log in to ask 6ix AI your own questions about Standard BioTools Inc.